Amino Acid Residue at Position 79 of Marburg Virus VP40 Confers Interferon Antagonism in Mouse Cells

Journal of Infectious Diseases

Volumn 212, Issue , 2015, Pages S219-S225

  Feagins, Alicia R ^a   Basler, Christopher F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Ci67 strain; interferon; Marburg virus; mouse adapted; Ravn virus; VP40

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GLYCINE; INTERFERON; JANUS KINASE 1; PROTEIN VP40; SERINE; STAT1 PROTEIN; STAT2 PROTEIN; AMINO ACID; MATRIX PROTEIN; VP40 PROTEIN, VIRUS;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MARBURGVIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VIRUS STRAIN; ANIMAL; CELL LINE; HEK293 CELL LINE; MARBURG HEMORRHAGIC FEVER; METABOLISM; PATHOGENICITY; VIROLOGY;

AMINO ACIDS; ANIMALS; CELL LINE; HEK293 CELLS; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; JANUS KINASE 1; MARBURG VIRUS DISEASE; MARBURGVIRUS; MICE; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; VIRAL MATRIX PROTEINS;

EID: 84937770754     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv010     Document Type: Article

References (30)

1. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: marburg and ebola viruses. In: Knipe DM, Howley PM, eds. Fields virology. 5th ed. Philadelphia: Lippincott Williams and Wilkins, 2007:1410-48.
2. Paessler S, Walker DH. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol 2013; 8:411-40.
3. World Health Organization. Marburg virus disease. 2014. http://www. who.int/csr/disease/marburg/en/.
4. Martinez O, Leung LW, Basler CF. The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge. Antiviral Res 2012; 93:416-28.
5. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5:375-86.
6. Harcourt BH, Sanchez A, Offermann MK. Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. Virology 1998; 252:179-88.
7. Harcourt BH, Sanchez A, Offermann MK. Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells. J Virol 1999; 73:3491-6.
8. Gupta M, Mahanty S, Ahmed R, Rollin PE. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-ICinduced IFN-alpha in vitro. Virology 2001; 284:20-5.
9. Kash JC, Muhlberger E, Carter V, et al. Global suppression of the host antiviral response by Ebola-and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 2006; 80:3009-20.
10. Basler CF, Mikulasova A, Martinez-Sobrido L, et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 2003; 77:7945-56.
11. Basler CF, Wang X, Muhlberger E, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 2000; 97: 12289-94.
12. Cardenas WB, Loo YM, GaleMJr, et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol 2006; 80:5168-78.
13. Leung DW, Prins KC, Borek DM, et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol 2010; 17:165-72.
14. Reid SP, Leung LW, Hartman AL, et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 2006; 80: 5156-67.
15. Reid SP, Valmas C, Martinez O, Sanchez FM, Basler CF. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol 2007; 81:13469-77.
16. Mateo M, Reid SP, Leung LW, Basler CF, Volchkov VE. Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J Virol 2010; 84:1169-75.
17. Xu W, Edwards MR, Borek DM, et al. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe 2014; 16:187-200.
18. Edwards MR, Johnson B, Mire CE, et al. The Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathway. Cell Rep 2014; 6:1017-25.
19. Valmas C, Grosch MN, Schumann M, et al. Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog 2010; 6:e1000721.
20. Warfield KL, Bradfute SB,Wells J, et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol 2009; 83:6404-15.
21. Lofts LL, Wells JB, Bavari S, Warfield KL. Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection process. J Virol 2011; 85:3905-17.
22. Valmas C, Basler CF. Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J Virol 2011; 85:4309-17.
23. Park MS, Garcia-Sastre A, Cros JF, Basler CF, Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J Virol 2003; 77:9522-32.
24. Best SM, Morris KL, Shannon JG, et al. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J Virol 2005; 79:12828-39.
25. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61.
26. Ebihara H, Takada A, Kobasa D, et al. Molecular determinants of Ebola virus virulence in mice. PLoS Pathog 2006; 2:e73.
27. Lofts LL, Ibrahim MS, Negley DL, Hevey MC, Schmaljohn AL. Genomic differences between guinea pig lethal and nonlethal Marburg virus variants. J Infect Dis 2007; 196(suppl 2):S305-12.
28. Volchkov VE, Chepurnov AA, Volchkova VA, Ternovoj VA, Klenk HD. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 2000; 277:147-55.
29. Warfield KL, Alves DA, Bradfute SB, et al. Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J 2007; 4:108.
30. Feagins AR, Basler CF. The VP40 protein of Marburg virus exhibits impaired budding and increased sensitivity to human tetherin following mouse-adaptation. J Virol 2014; 88:14440-50.